The KalaCORE consortium was formed from four organisations, namely Drugs for Neglected Diseases Initiative (DNDi), the London School of Hygiene & Tropical Medicine (LSHTM), Médecins Sans Frontières (MSF), and Mott MacDonald. Each of these organisations brought distinct and complementary skills to delivery of the programme. KalaCORE ended in March 2019.
KalaCORE aimed to make significant contributions to reducing the health and economic impact of VL, by supporting progress towards elimination in South Asia and building stronger capacity for an effective VL response in East Africa.
In South Asia (India, Bangladesh and Nepal), we have focused on providing intensive support for strengthening treatment access, with targets of at least 50 treatment centres meeting quality criteria and 80% of service providers trained in endemic areas of the region; the programme has also targeted vector control, the private sector and community response, and VL surveillance in the region.
In East Africa (Ethiopia, Sudan and South Sudan), we have aimed at expanding access to diagnosis and treatment, with targets of at least 12 treatment centres meeting quality criteria and 80% of service providers trained in endemic areas; the programme has also focussed on ensuring endemic areas are mapped, effective vector control methods are evaluated and scaled-up, with a target of 80% of VL outbreaks in the region to be responded to within four months.